Heart Attacks, Cancer and strokes. Preventative approaches Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Heart Attacks, Cancer and strokes. Preventative approaches

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jrhana	12/29/2009 8:04:10 AM
	of 39296

Pfizer licenses apoA-I Milano to the Medicines Company theheart.org December 23, 2009 \| Lisa Nainggolan Parsippany, NJ and New York, NY- The Medicines Company has acquired from Pfizer exclusive worldwide licensing of apoA-I Milano, the naturally occurring variant of a protein found in high-density-lipoprotein cholesterol [1]. In nonclinical models, apoA-I Milano rapidly removed excess cholesterol from artery walls, stabilizing and causing regression of atherosclerotic plaques, the companies note. And a phase 1-2 study in a small number of patients showed significant reductions in coronary plaque volume of 4.2% in six weeks, they add [2]. ApoA-I Milano was originally developed by Esperion Therapeutics, which was acquired by Pfizer in 2004. The Medicines Company has paid $10 million up front to Pfizer for apoA-I Milano, and the Pfizer will receive additional payments upon achievement of certain milestones, to a total of $410 million, as well as single-digit royalty payments on any worldwide net sales of the compound.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next